Full text is available at the source.
Abstract
Sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce cardiovascular and kidney events in patients with type 2 diabetes.
- These medications are particularly associated with benefits in patients who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.
- Despite potential benefits, the prescribing rates for these treatments remain low among eligible patients.
Simplified